The National Institute on Drug Abuse (NIDA) offers the Translational Avant-Garde Award (DP1) to visionary basic and clinical researchers. This grant supports the translation of research discoveries into safe and effective medications for diseases of addiction. NIDA seeks significant advances in treating disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Funded products can be pharmaceuticals (small molecules) or biologics like vaccines. Applications may focus on pharmacotherapy, specific symptoms such as withdrawal or craving, or new formulations of existing medications. This initiative aims to accelerate the development of innovative treatments to combat substance use disorders.
Opportunity ID: 51324
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-10-013 |
| Funding Opportunity Title: | 2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 26, 2010 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jul 02, 2010 |
| Current Closing Date for Applications: | Jul 02, 2010 |
| Archive Date: | Aug 02, 2010 |
| Estimated Total Program Funding: | $2,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Small businesses For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Private institutions of higher education City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of diseases of addiction. Through this funding FOA, the National Institute on Drug Abuse (NIDA) is committed to making significant advances in the development of safe and efficacious products for the treatment of disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use or abuse. These products can be pharmaceuticals (small molecules) or biologics. Biologics include medicinal products such as vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the pharmacotherapy of one or various disorders. Applications may also focus on the specific symptoms of the disorder such as withdrawal, craving or relapse. Testing of new formulations of marketed medications that are available for other indications, or new combinations of existing medications, which may be promising candidates for the treatment of diseases of addiction is within the scope of this FOA. The 2010 Translational Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-10-095. Pre-applications will be evaluated by a group of external reviewers. Those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA (DP1). The 2010 Avant-Garde awardees will be selected from this group of applicants. Mechanism of Support. This FOA will utilize the DP1 grant mechanism. Pre-applications for 2010 Translational Avant-Garde Awards were encouraged under PAR-10-095. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIDA intends to commit $2 million for 2-3 awards in fiscal 2010. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-10-013.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.279 | ADOBE-FORMS-B | Use for submissions intended for due dates of January 25, 2010 and beyond | PKG00016040 | Jun 02, 2010 | Jul 02, 2010 | View |
Package 1
Mandatory forms
51324 RR_SF424_1_2-1.2.pdf
51324 PerformanceSite_1_3-1.3.pdf
51324 RR_OtherProjectInfo_1_2-1.2.pdf
51324 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
51324 PHS_CoverLetter_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
